GRM6 and breast cancer: Further studies are needed to improve vector–promoter combinations and potentially the mode of administration (and therefore the efficiency of ON-BC transduction), but our findings are encouraging and will serve as a base to develop further gene therapy trials for cCSNB due to mutations in GRM6.